Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Everest Medicines Ltd. ( (HK:1952) ) is now available.
Everest Medicines Ltd. announced that its controlling shareholder, CBC Group, plans to sell 25,000,000 shares, representing approximately 7.63% of the company’s issued share capital, to global long-only and healthcare specialist investors. This move aims to broaden the company’s shareholder base with high-quality investors to support its long-term growth. The company remains committed to its strategic focus areas, including increasing sales of its key products, advancing regulatory processes, and developing next-generation treatments, without any material changes to its business operations or financial position.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products. The company is engaged in the sale of NEFECON®, a unique drug for IgAN, and XERAVA®, an antibiotic, while also advancing regulatory processes for VELSIPITY® and developing innovative treatments like mRNA cancer vaccines and in-vivo CAR-T programs.
Average Trading Volume: 5,353,387
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.93B
See more insights into 1952 stock on TipRanks’ Stock Analysis page.